AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,042.00p
   
  • Change Today:
    -164.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.29m
  • Volume: 2,329,887
  • Market Cap: £171,184m
  • RiskGrade: 123

AstraZeneca breast cancer drug shows 'significant' improvement in trial

By Frank Prenesti

Date: Wednesday 26 Oct 2022

LONDON (ShareCast) - (Sharecast News) - AstraZeneca said its capivasertib breast cancer drug combined with Faslodex hormone treatment demonstrated a "statistically significant and clinically meaningful improvement" in progression-free patient (PFS) survival during a late-stage trial.
The trial met both primary endpoints, improving PFS in the overall patient population and in a prespecified biomarker subgroup of patients whose tumours had qualifying alterations, AstraZeneca said on Wednesday.

Results were measured against patients given a placebo plus Faslodex. The trial covered patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy.

"Although the overall survival (OS) data were immature at the time of the analysis, early data are encouraging. The trial will continue to assess OS as a key secondary endpoint," the company added.

Breast cancer is the most common cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020. Approximately 70% of breast cancer tumours are considered HR-positive and HER2-low or negative.

Endocrine therapies are widely used for the treatment of HR-positive breast cancer, but many patients with advanced disease develop resistance to inhibitors and estrogen receptor-targeting therapies, "underscoring the need for additional options", AstraZeneca said.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,042.00p
Change Today -164.00p
% Change -1.46 %
52 Week High 13,276.00p
52 Week Low 9,501.00p
Volume 2,329,887
Shares Issued 1,550.29m
Market Cap £171,184m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average92.03% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average6.17% above the market average
52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average
Income
88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average88.65% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 31-Oct-2024

Time Volume / Share Price
16:09 179,211 @ 11,160.00p
16:51 488 @ 11,042.00p
16:51 142 @ 11,042.00p
16:35 3,725 @ 11,042.00p
16:35 75 @ 11,042.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page